Evidence map›Paper›PMID 25852911›Full record

ArticleClinical kidney journal2014

Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients.

Bodil Sjöberg, Sunna Snaedal, Peter Stenvinkel, Abdul Rashid Qureshi, Olof Heimbürger, Peter Bárány

Open access · bronzeAbstract read
In one paragraph

Article in Clinical kidney journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bodil SjöbergDivision of Renal Medicine , CLINTEC, Karolinska Institutet , Stockholm , Sweden.
Sunna SnaedalDivision of Renal Medicine , CLINTEC, Karolinska Institutet , Stockholm , Sweden.
Peter StenvinkelDivision of Renal Medicine , CLINTEC, Karolinska Institutet , Stockholm , Sweden.
Abdul Rashid QureshiDivision of Baxter Novum , CLINTEC, Karolinska Institutet , Stockholm , Sweden.
Olof HeimbürgerDivision of Renal Medicine , CLINTEC, Karolinska Institutet , Stockholm , Sweden.
Peter BárányDivision of Renal Medicine , CLINTEC, Karolinska Institutet , Stockholm , Sweden.
Karolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory markers vary considerably over time in haemodialysis (HD) patients, yet the variability is poorly defined. The aim of the study was to assess changes of plasma levels of pentraxin-3 (PTX-3), C-reactive protein (CRP), albumin and homocysteine (Hcy) over 3 months and the association between the changes in these biomarkers and mortality.

methodsIn 188 prevalent HD patients, inflammatory markers were measured at inclusion and after 3 months. Mortality was recorded during a median follow-up of 41 months. The changes of the biomarker levels were categorized according to change in tertile for the specific biomarker. The variation was calculated as the intra-class correlation (ICC). Mortality was analysed by Kaplan-Meier and Cox proportional hazards model. The predictive strength was calculated for single measurements and for the variation of each inflammatory marker.

resultsThe intra-individual variation (low ICC) was largest for PTX-3 [ICC 0.44; 95% confidence interval (CI): 0.33-0.55], albumin (ICC 0.58; 95% CI: 0.49-0.67) and CRP (ICC 0.59; 95% CI: 0.51-0.68) and lowest for Hcy (ICC 0.81; 95% CI: 0.77-0.86). During follow-up, 88 patients died.

conclusionsPTX-3 measurements are less stable and show higher variation within patients than CRP, albumin and Hcy. Persistently elevated PTX-3 levels are associated with high mortality. Moreover, in multivariate logistic regression we found that stable high PTX-3 adds to the mortality risk, even after inclusion of clinical factors and the three other biomarkers. The associations of decreasing albumin levels as well as low Hcy levels with worse outcome reflect protein-energy wasting.

Indexed as

end-stage renal diseaseHDinflammationpentraxin 3variation

Identifiers

PMID25852911
PMCPMC4377816
OpenAlexW2135155199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.